Stephen Adams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen Adams has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
James M Wright
Department of Anesthesiology, Pharmacology and Therapeutics; University of British Columbia; Vancouver Canada
3 shared publications- Adrienne Stevens
Centre for Immunization Programs, Infectious Diseases & Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, Ontario, Canada
2 shared publications - Alyssa Chen
Cochrane Hypertension Review Group, Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine University of British Columbia Vancouver British Columbia Canada
2 shared publications - Beverley Shea
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
2 shared publications - Carole Lunny
Cochrane Hypertension Review Group, Therapeutics Initiative, University of British Columbia, Vancouver, BC, Canada
2 shared publications - Emma K. Reid
Nova Scotia Health Halifax Nova Scotia Canada
2 shared publications
Latest Publications
- 18 September 2023
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (9) , CD013673
Pravastatin for lowering lipids
Background A detailed summary and meta‐analysis of the dose‐related effect of pravastatin on lipids is not available. Objectives Primary objective To assess the pharmacology of pravastatin by characterizing the dose‐related effect and variability of the effect of pravastatin on the surrogate marker: low‐density lipoprotein (LDL cholesterol). The effect of pravastatin on morbidity and mortality is not the objective of this systematic review. Secondary objectives • To assess the dose‐related effect and variability of effect of pravastatin on the following surrogate markers: total cholesterol; high‐density lipoprotein (HDL cholesterol); and triglycerides. • To assess the effect of pravastatin on withdrawals due to adverse effects. Search methods The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials (RCTs) up to September 2021: CENTRAL (2021, Issue 8), Ovid MEDLINE, Ovid Embase, Bireme LILACS, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions. Selection criteria Randomized placebo‐controlled trials evaluating the dose response of different fixed doses of pravastatin on blood lipids over a duration of three to 12 weeks in participants of any age with and without evidence of cardiovascular disease. Data collection and analysis Two review authors independently assessed eligibility criteria for studies to be included, and extracted data. We entered lipid data from placebo‐controlled trials into Review Manager 5 as continuous data and withdrawal due to adverse effects (WDAEs) data as dichotomous data. We searched for WDAEs information from all trials. We assessed all trials using Cochrane's risk of bias tool under the categories of sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other potential biases. Main results Sixty‐four RCTs evaluated the dose‐related efficacy of pravastatin in 9771 participants. The participants were of any age, with and without evidence of cardiovascular disease, and pravastatin effects were studied within a treatment period of three to 12 weeks. Log dose‐response data over the doses of 5 mg to 160 mg revealed strong linear dose‐related effects on blood total cholesterol and LDL cholesterol, and a weak linear dose‐related effect on blood triglycerides. There was no dose‐related effect of pravastatin on blood HDL cholesterol. Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%, total cholesterol by 16.1% to 23.3%,and triglycerides by 5.8% to 20.0%. The certainty of evidence for these effects was judged to be moderate to high. For every two‐fold dose increase there was a 3.4% (95% confidence interval (CI) 2.2 to 4.6) decrease in blood LDL cholesterol. This represented a dose‐response slope that was less than the other studied statins: atorvastatin, rosuvastatin, fluvastatin, pitavastatin and cerivastatin. From other systematic reviews we conducted on statins for its effect to reduce LDL cholesterol, pravastatin is similar to fluvastatin, but has a decreased effect compared to atorvastatin, rosuvastatin, pitavastatin and cerivastatin. The effect of pravastatin compared to placebo on WADES has a risk ratio (RR) of 0.81 (95% CI 0.63 to 1.03). The certainty of evidence was judged to be very low. Authors' conclusions Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose‐dependent linear fashion. This review did not provide a good estimate of the incidence of harms associated with pravastatin because of the lack of reporting of adverse effects in 48.4% of the randomized placebo‐controlled trials.
- 18 September 2023
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (9) , CD013673
Pravastatin for lowering lipids
Background A detailed summary and meta‐analysis of the dose‐related effect of pravastatin on lipids is not available. Objectives Primary objective To assess the pharmacology of pravastatin by characterizing the dose‐related effect and variability of the effect of pravastatin on the surrogate marker: low‐density lipoprotein (LDL cholesterol). The effect of pravastatin on morbidity and mortality is not the objective of this systematic review. Secondary objectives • To assess the dose‐related effect and variability of effect of pravastatin on the following surrogate markers: total cholesterol; high‐density lipoprotein (HDL cholesterol); and triglycerides. • To assess the effect of pravastatin on withdrawals due to adverse effects. Search methods The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials (RCTs) up to September 2021: CENTRAL (2021, Issue 8), Ovid MEDLINE, Ovid Embase, Bireme LILACS, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions. Selection criteria Randomized placebo‐controlled trials evaluating the dose response of different fixed doses of pravastatin on blood lipids over a duration of three to 12 weeks in participants of any age with and without evidence of cardiovascular disease. Data collection and analysis Two review authors independently assessed eligibility criteria for studies to be included, and extracted data. We entered lipid data from placebo‐controlled trials into Review Manager 5 as continuous data and withdrawal due to adverse effects (WDAEs) data as dichotomous data. We searched for WDAEs information from all trials. We assessed all trials using Cochrane's risk of bias tool under the categories of sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other potential biases. Main results Sixty‐four RCTs evaluated the dose‐related efficacy of pravastatin in 9771 participants. The participants were of any age, with and without evidence of cardiovascular disease, and pravastatin effects were studied within a treatment period of three to 12 weeks. Log dose‐response data over the doses of 5 mg to 160 mg revealed strong linear dose‐related effects on blood total cholesterol and LDL cholesterol, and a weak linear dose‐related effect on blood triglycerides. There was no dose‐related effect of pravastatin on blood HDL cholesterol. Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%, total cholesterol by 16.1% to 23.3%,and triglycerides by 5.8% to 20.0%. The certainty of evidence for these effects was judged to be moderate to high. For every two‐fold dose increase there was a 3.4% (95% confidence interval (CI) 2.2 to 4.6) decrease in blood LDL cholesterol. This represented a dose‐response slope that was less than the other studied statins: atorvastatin, rosuvastatin, fluvastatin, pitavastatin and cerivastatin. From other systematic reviews we conducted on statins for its effect to reduce LDL cholesterol, pravastatin is similar to fluvastatin, but has a decreased effect compared to atorvastatin, rosuvastatin, pitavastatin and cerivastatin. The effect of pravastatin compared to placebo on WADES has a risk ratio (RR) of 0.81 (95% CI 0.63 to 1.03). The certainty of evidence was judged to be very low. Authors' conclusions Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose‐dependent linear fashion. This review did not provide a good estimate of the incidence of harms associated with pravastatin because of the lack of reporting of adverse effects in 48.4% of the randomized placebo‐controlled trials.
- 27 March 2023
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (3)
Lovastatin for lowering lipids
- 27 March 2023
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (3)
Lovastatin for lowering lipids
- 24 February 2023
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (2)
Simvastatin for lowering lipids
- 24 February 2023
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (2)
Simvastatin for lowering lipids
- Open Access
- 23 January 2022
- Published by Wiley in Research Synthesis Methods
- Vol. 13 (3) , 315-329
A new taxonomy was developed for overlap across 'overviews of systematic reviews': A meta‐research study of research waste
Multiple ‘overviews of reviews’ conducted on the same topic (“overlapping overviews”) represent a waste of research resources and can confuse clinicians making decisions amongst competing treatments. We aimed to assess the frequency and characteristics of overlapping overviews. MEDLINE, Epistemonikos and Cochrane Database of Systematic Reviews were searched for overviews that: synthesized reviews of health interventions and conducted systematic searches. Overlap was defined as: duplication of PICO eligibility criteria, and not reported as an update nor a replication. We categorized overview topics according to 22 WHO ICD‐10 medical classifications, overviews as broad or narrow in scope, and overlap as identical, nearly identical, partial, or subsumed. Subsummation was defined as when broad overviews subsumed the populations, interventions and at least one outcome of another overview. Of 541 overviews included, 169 (31%) overlapped across similar PICO, fell within 13 WHO ICD‐10 medical classifications, and 62 topics. 148/169 (88%) overlapping overviews were broad in scope. Fifteen overviews were classified as having nearly identical overlap (9%); 123 partial overlap (73%), and 31 subsumed (18%) others. One third of overviews overlapped in content and a majority covered broad topic areas. A multiplicity of overviews on the same topic adds to the ongoing waste of research resources, time, and effort across medical disciplines. Authors of overviews can use this study and the sample of overviews to identify gaps in the evidence for future analysis, and topics that are already studied, which do not need to be duplicated.
- 23 January 2022
- Published by Wiley in Research Synthesis Methods
- Vol. 13 (3) , 315-329
Open AccessA new taxonomy was developed for overlap across 'overviews of systematic reviews': A meta‐research study of research waste
Multiple ‘overviews of reviews’ conducted on the same topic (“overlapping overviews”) represent a waste of research resources and can confuse clinicians making decisions amongst competing treatments. We aimed to assess the frequency and characteristics of overlapping overviews. MEDLINE, Epistemonikos and Cochrane Database of Systematic Reviews were searched for overviews that: synthesized reviews of health interventions and conducted systematic searches. Overlap was defined as: duplication of PICO eligibility criteria, and not reported as an update nor a replication. We categorized overview topics according to 22 WHO ICD‐10 medical classifications, overviews as broad or narrow in scope, and overlap as identical, nearly identical, partial, or subsumed. Subsummation was defined as when broad overviews subsumed the populations, interventions and at least one outcome of another overview. Of 541 overviews included, 169 (31%) overlapped across similar PICO, fell within 13 WHO ICD‐10 medical classifications, and 62 topics. 148/169 (88%) overlapping overviews were broad in scope. Fifteen overviews were classified as having nearly identical overlap (9%); 123 partial overlap (73%), and 31 subsumed (18%) others. One third of overviews overlapped in content and a majority covered broad topic areas. A multiplicity of overviews on the same topic adds to the ongoing waste of research resources, time, and effort across medical disciplines. Authors of overviews can use this study and the sample of overviews to identify gaps in the evidence for future analysis, and topics that are already studied, which do not need to be duplicated.
- 10 October 2021
- Published by Wiley in Research Synthesis Methods
- Vol. 13 (1) , 109-120
Bibliometric study of ‘overviews of systematic reviews’ of health interventions: Evaluation of prevalence, citation and journal impact factor
Overviews synthesising the results of multiple systematic reviews help inform evidence‐based clinical practice. In this first of two companion papers, we evaluate the bibliometrics of overviews, including their prevalence and factors affecting citation rates and journal impact factor (JIF). We searched MEDLINE, Epistemonikos and Cochrane Database of Systematic Reviews (CDSR). We included overviews that: (a) synthesised reviews, (b) conducted a systematic search, (c) had a methods section and (d) examined a healthcare intervention. Multivariable regression was conducted to determine the association between citation density, JIF and six predictor variables. We found 1218 overviews published from 2000 to 2020; the majority (73%) were published in the most recent 5‐year period. We extracted a selection of these overviews (n = 541; 44%) dated from 2000 to 2018. The 541 overviews were published in 307 journals; CDSR (8%), PLOS ONE (3%) and Sao Paulo Medical Journal (2%) were the most prevalent. The majority (70%) were published in journals with impact factors between 0.05 and 3.97. We found a mean citation count of 10 overviews per year, published in journals with a mean JIF of 4.4. In multivariable analysis, overviews with a high number of citations and JIFs had more authors, larger sample sizes, were open access and reported the funding source. An eightfold increase in the number of overviews was found between 2009 and 2020. We identified 332 overviews published in 2020, which is equivalent to one overview published per day. Overviews perform above average for the journals in which they publish.
- 10 October 2021
- Published by Wiley in Research Synthesis Methods
- Vol. 13 (1) , 109-120
Bibliometric study of ‘overviews of systematic reviews’ of health interventions: Evaluation of prevalence, citation and journal impact factor
Overviews synthesising the results of multiple systematic reviews help inform evidence‐based clinical practice. In this first of two companion papers, we evaluate the bibliometrics of overviews, including their prevalence and factors affecting citation rates and journal impact factor (JIF). We searched MEDLINE, Epistemonikos and Cochrane Database of Systematic Reviews (CDSR). We included overviews that: (a) synthesised reviews, (b) conducted a systematic search, (c) had a methods section and (d) examined a healthcare intervention. Multivariable regression was conducted to determine the association between citation density, JIF and six predictor variables. We found 1218 overviews published from 2000 to 2020; the majority (73%) were published in the most recent 5‐year period. We extracted a selection of these overviews (n = 541; 44%) dated from 2000 to 2018. The 541 overviews were published in 307 journals; CDSR (8%), PLOS ONE (3%) and Sao Paulo Medical Journal (2%) were the most prevalent. The majority (70%) were published in journals with impact factors between 0.05 and 3.97. We found a mean citation count of 10 overviews per year, published in journals with a mean JIF of 4.4. In multivariable analysis, overviews with a high number of citations and JIFs had more authors, larger sample sizes, were open access and reported the funding source. An eightfold increase in the number of overviews was found between 2009 and 2020. We identified 332 overviews published in 2020, which is equivalent to one overview published per day. Overviews perform above average for the journals in which they publish.